M.T.3
19.9.2023 17:01:29 CEST | Business Wire | Press release
Malignant Tumor Treatment Technologies, Inc. (Headquarters: Tokyo; President and CEO: Toshiyasu Miyazaki; “M.T.3”) announced today that the Japanese pharmaceutical regulatory agency, the Ministry of Agriculture, Forestry, and Fisheries, has granted approval for LAVURCHIN® as a radiation sensitizing agent for dogs with stage III or stage IV nasal cavity tumors.
Radiation therapy, a crucial treatment for malignant tumors that cannot be completely removed through surgery, has seen significant advancements in recent years in both human and veterinary medicine. However, challenges such as limitations on the number of radiation sessions and decreased effectiveness as tumors progress have highlighted the need for a radiation sensitizing agent to enhance treatment outcomes. Despite several candidate substances being studied, none have obtained pharmaceutical approval due to concerns about side effects.
After a long and challenging endeavor lasting over two and a half decades, "LAVURCHIN®" has emerged as a groundbreaking solution as the world’s first radiation sensitizing agent in the veterinary field approved by the Japanese Ministry of Agriculture, Forestry, and Fisheries (MAFF), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). Derived from marine organisms, including sea urchins from Hokkaido, a northern region of Japan, and deep-sea seaweed, this innovative agent not only enhances the effects of radiation therapy but also minimizes damage to normal tissues, ensuring high safety standards.
"We are delighted to announce the approval of LAVURCHIN® as the world's first radiation sensitizing agent for dogs," said Toshiyasu Miyazaki, President and CEO of M.T.3. "This significant milestone is a testament to our commitment to advancing cancer treatment and improving the lives of both animals and humans. We will continue our endeavors to make LAVURCHIN® available to those in need around the world."
In parallel with the Japanese approval, M.T.3 is conducting clinical research on "LAVURCHIN®" in the United States, demonstrating a global perspective. The company envisions bringing this revolutionary product to markets worldwide, including the United States, Europe, and Asia. Furthermore, future expansion into human medicine is also being considered.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911165281/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
W. L. Gore & Associates Launches GORE® Battery Vents – MultiVent Series at the Battery Show12.10.2026 14:00:00 CEST | Press release
The integrated battery vent combines pressure equalization, moisture protection, and resealable thermal-runaway evacuation in a single part, with one opening in the pack wall. Today, W. L. Gore & Associates (Gore) introduced GORE® Battery Vents – MultiVent Series at The Battery Show North America 2026, a new integrated venting architecture that combines all three functions into a single device. Designed for lithium-ion battery packs in electric vehicles and energy storage systems, GORE® MultiVent is an integrated battery vent: one device that equalizes pressure, protects against moisture and evacuates gas during thermal runaway, then reseals. It gives pack designers an alternative to combining dual-stage vents, separate evacuation valves and desiccants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012625188/en/ GORE® MultiVent GORE MultiVent builds on technology Gore acquired from Vernay Laboratories in 2026 and combine
Echodyne and ACS Sign Strategic Collaboration Agreement to Advance Counter-UAS Capabilities Worldwide12.10.2026 14:00:00 CEST | Press release
Successful integration of EchoShield® radar with ACS’s Bullfrog™ autonomousweapon station delivers precise tracking and affordable kinetic defeat across land and maritime missions. Echodyne, the radar platform company, and ACS, a precision robotics company for defense, today announced the signing of a Strategic Collaboration Agreement to accelerate the development, demonstration, and deployment of integrated counter-unmanned aircraft system (C-UAS) solutions. The agreement establishes collaboration across Echodyne’s high-performance commercial counter-UAS radar hardware and software roadmaps and ACS’s Bullfrog robotic weapon station capabilities, and follows the recent announcement of each company’s award from Joint Interagency Task Force 401 for Domestic Shield, the JIATF-401 C-UAS Marketplace, and other critical counter-drone requirements. Bullfrog combines computer vision, autonomous control, and precision robotics with existing weapon systems to detect, track, identify, and engage
Doctors, Public Health Experts and Dental Leaders Call for Oral Health to Become Part of Everyday Health Care12.10.2026 13:34:00 CEST | Press release
New international consensus connects healthier teeth and gums with overall health and identifies practical daily steps, including effective plaque removal, that can help prevent oral disease Doctors, public-health experts and dental leaders are calling for oral health to be treated as part of overall health. Their message is clear: healthier teeth and gums matter beyond the mouth, and effective daily prevention should become a routine part of health care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015403348/en/ Oral health is part of overall health. Leading health experts are calling for oral health to become part of everyday health care, with prevention starting at home through healthier habits and daily care of teeth and gums. The new international consensus goes well beyond dentistry. It brought together experts in periodontology, cardiology, diabetes care, family medicine, public health, social care and health edu
Pacific Defense Launches NEXUS, a Converged C2 and Electromagnetic Warfare Mission System12.10.2026 13:30:00 CEST | Press release
COTS, open-architecture system brings communications, networking, edge computing, sensing and electronic effects onto a common SOSA™ and CMOSS-aligned architecture Pacific Defense, a leading provider of open-architecture C5ISR and electronic warfare mission systems, today announced the launch of NEXUS, a Commercial Off-the-Shelf (COTS) mission system that converges command and control, communications, networking, edge computing, and electronic warfare on a common, adaptable architecture. Built on a Modular Open Systems Approach (MOSA) aligned to SOSA™, CMOSS and OpenVPX™, NEXUS enables mission-specific configurations across mobile, fixed-site, maritime, and airborne operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012010656/en/ NEXUS converges EW and C5ISR in one, open-architecture system for missions across ground, maritime, and airborne operations. NEXUS brings capabilities traditionally integrated through sep
Trading Central Expands UCITS ETF Range to U.S. and Global Equities12.10.2026 13:24:00 CEST | Press release
Three funds powered by TC Quantamental Rating® are now available to brokers and distributors across Europe. Trading Central SA ("Trading Central") today announced the launch of two new UCITS ETFs in partnership with HANetf, Europe’s first and leading white-label UCITS ETF and ETC platform. The new funds join the Trading Central Quant Europe 50 Equity UCITS ETF (TCQE), launched on 13 August 2026, bringing the Trading Central Quant ETF range to three. NEW – Trading Central Quant U.S. 50 Equity UCITS ETF (TCQU) | ISIN: IE000M5KXSP3 NEW – Trading Central Quant Global 50 Equity UCITS ETF (TCQW) | ISIN: IE000YM4FP49 Trading Central Quant Europe 50 Equity UCITS ETF (TCQE) | ISIN: IE000DN0XQM1 All three ETFs are available to trade on Euronext Paris, Euronext Milan, Euronext Dublin, the London Stock Exchange, and Börse Frankfurt. J.P. Morgan serves as fund administrator and custodian, while GTX acts as the market maker across these exchanges. This launch marks Trading Central’s continued expans
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom